| Literature DB >> 34070514 |
Camille Roubille1,2, Soledad Henriquez3,4, Cédric Mercuzot1, Claire Duflos5, Bertrand Dunogue3,4, Karine Briot4,6, Loic Guillevin3,4, Benjamin Terrier3,4, Pierre Fesler1,2.
Abstract
Despite improvement in the prognosis of ANCA-associated vasculitides (AAVs), increased mortality, mainly from a cardiovascular origin, persists. We aimed to determine the role of cardiovascular risk factors (CVRFs) on the occurrence of major cardiovascular events (MACEs) in AAVs. Patients with AAVs were successively included in a prospective cohort study, which assessed CVRFs (defined by age >50 years in men and >60 years in women, personal history of cardiovascular disease, smoking status, obesity, diabetes, dyslipidemia, hypertension, and sedentary lifestyle), the use of glucocorticoids and immunosuppressive agents at baseline and during follow-up, and the occurrence of MACEs. One hundred and three patients were included, with a median follow-up time of 3.5 years. In the glucocorticoids and cyclophosphamide adjusted multivariate analysis, the occurrence of MACEs was associated with older age (p = 0.001, OR = 14.71, 95% CI (confidence interval) = 2.98-72.68), cardiovascular history (p = 0.007, OR (odds ratio) = 6.54, 95% CI = 1.66-25.71), sedentary lifestyle (p = 0.011, OR = 4.50, 95% CI = 1.42-14.29), hypertension (p = 0.017, OR = 5.04, 95% CI = 1.33-19.12), and dyslipidemia (p = 0.03, OR = 3.86, 95% CI = 1.14-13.09). The occurrence of MACEs was associated with the number of CVRFs (p < 0.001), but not with the use of glucocorticoids or cyclophosphamide (p = 0.733 and p = 0.339, respectively). The implementation of a screening and management program for modifiable CVRFs, particularly hypertension, sedentary lifestyle, and dyslipidemia, may be beneficial for AAV patients in order to reduce their cardiovascular risk.Entities:
Keywords: antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis; cardiovascular risk; cardiovascular risk factors; dyslipidemia; hypertension; sedentary lifestyle
Year: 2021 PMID: 34070514 DOI: 10.3390/jcm10112299
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241